Should I buy or sell Orchestra BioMed stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchestra BioMed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OBIO shares. View OBIO analyst ratings or view top-rated stocks .

What is Orchestra BioMed's stock price target for 2024?

3 Wall Street analysts have issued 1-year price targets for Orchestra BioMed's stock. Their OBIO share price targets range from $15.00 to $20.00. On average, they expect the company's stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 168.0% from the stock's current price. View analysts price targets for OBIO or view top-rated stocks among Wall Street analysts .

How have OBIO shares performed in 2023?

Orchestra BioMed's stock was trading at $9.12 at the start of the year. Since then, OBIO stock has decreased by 28.4% and is now trading at $6.53. View the best growth stocks for 2023 here .

When is Orchestra BioMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our OBIO earnings forecast .

How were Orchestra BioMed's earnings last quarter?

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) released its earnings results on Monday, November, 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.01. The business earned $0.42 million during the quarter, compared to the consensus estimate of $0.89 million.

Who are Orchestra BioMed's major shareholders?

Orchestra BioMed's stock is owned by a number of institutional and retail investors. Top institutional investors include Charles Schwab Investment Management Inc. (0.43%), Northern Trust Corp (0.40%), TD Asset Management Inc (0.26%), Arkadios Wealth Advisors (0.14%), Bank of New York Mellon Corp (0.11%) and The Manufacturers Life Insurance Company (0.11%).

How do I buy shares of Orchestra BioMed?

Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Orchestra BioMed Stock Price, News & Analysis (NASDAQ:OBIO)

$6.53

+0.02 (+0.31%)

(As of 12:22 PM ET)

Compare

Today's Range: $6.30
▼
$6.62
50-Day Range: $4.42
▼
$10.37
52-Week Range: $4.26
▼
$23.39

Volume: 6,244 shs
Average Volume: 101,802 shs
Market Capitalization: $233.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.50

Orchestra BioMed MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 168.0% Upside
$17.50 Price Target
Short Interest: Bearish
5.93% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.14
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.53) to ($1.72) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

858th out of 949 stocks

Surgical & Medical Instruments Industry

88th out of 96 stocks

3.5

Analyst's Opinion

Consensus Rating
Orchestra BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.50, Orchestra BioMed has a forecasted upside of 168.0% from its current price of $6.53.
Amount of Analyst Coverage
Orchestra BioMed has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.93% of the float of Orchestra BioMed has been sold short.
Short Interest Ratio / Days to Cover
Orchestra BioMed has a short interest ratio ("days to cover") of 9.2.
Change versus previous month
Short interest in Orchestra BioMed has recently increased by 1.56%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Orchestra BioMed does not currently pay a dividend.
Dividend Growth
Orchestra BioMed does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OBIO.

2.9

News and Social Media Coverage

News Sentiment
Orchestra BioMed has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Orchestra BioMed this week, compared to 0 articles on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Orchestra BioMed insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 30.16% of the stock of Orchestra BioMed is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Orchestra BioMed are expected to decrease in the coming year, from ($1.53) to ($1.72) per share.
Price to Book Value per Share Ratio
Orchestra BioMed has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Orchestra BioMed Stock (NASDAQ:OBIO)

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

OBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OBIO Stock News Headlines

November 24, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Boosted by Lifesci Capital

November 16, 2023 | finanznachrichten.de

Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Bicycle Therapeutics (BCYC)

November 14, 2023 | uk.finance.yahoo.com

Orchestra BioMed Holdings, Inc. (OBIO)

November 13, 2023 | finance.yahoo.com

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

November 9, 2023 | finance.yahoo.com

Orchestra BioMed to Present at Upcoming Investor Conferences

November 7, 2023 | msn.com

AxoGen Non-GAAP EPS of $0.01 beats by $0.07, revenue of $41.3M beats by $1.03M

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

October 25, 2023 | finanznachrichten.de

OBiO Technology (Shanghai) Corp., Ltd.: OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product

October 21, 2023 | wsj.com

Orchestra BioMed Holdings Inc.

October 12, 2023 | seekingalpha.com

Orchestra BioMed files prospectus for issuance of up to 1.93M shares

October 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Reneo Pharmaceuticals (RPHM), Pulmonx (LUNG) and Orchestra BioMed Holdings (OBIO)

September 22, 2023 | finance.yahoo.com

Lab Notes: Main Line firm spins off company that will focus on OTC product pipeline

September 19, 2023 | markets.businessinsider.com

Orchestra BioMed Holdings (OBIO) Gets a Buy from LifeSci Capital

September 19, 2023 | markets.businessinsider.com

Crude Oil Rises Over 1%; Revance Therapeutics Shares Plummet

September 19, 2023 | msn.com

Why Shares of Orchestra BioMed Jumped Tuesday

September 19, 2023 | finance.yahoo.com

Rebel's Edge - September 19: $NIO, $BHC, $OBIO, and the Firing of MSU's Football Coach

September 19, 2023 | baystreet.ca

Orchestra, Medtronic Join Forces

August 11, 2023 | finanznachrichten.de

Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

August 11, 2023 | finance.yahoo.com

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

August 10, 2023 | msn.com

Chardan Capital Reiterates Orchestra BioMed Holdings (OBIO) Buy Recommendation

August 8, 2023 | finance.yahoo.com

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

August 2, 2023 | uk.investing.com

Orchestra Biomed Holdings Inc (OBIO)

July 31, 2023 | finance.yahoo.com

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) stock most popular amongst retail investors who own 36%, while hedge funds hold 28%

June 28, 2023 | finance.yahoo.com

Why Shares of Orchestra BioMed Holdings Jumped Wednesday

June 26, 2023 | finance.yahoo.com

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

See More Headlines

Receive OBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OBIO
CUSIP: N/A
CIK: 1814114
Web: orchestrabiomed.com
Phone: 646-597-6980
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.50
High Stock Price Target: $20.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +168.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,730,000.00
Net Margins: N/A
Pretax Margin: -22,322.03%
Return on Equity: -23.18%
Return on Assets: -13.60%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.13
Quick Ratio: 5.13

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.23 per share
Price / Book: 2.93

Miscellaneous

Outstanding Shares: 35,740,000
Free Float: N/A
Market Cap: $233.38 million
Optionable: Not Optionable
Beta: -0.18

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. David P. Hochman (Age 48)
Founder, Chairman of the Board of Directors & CEO
Comp: $790k
Mr. Darren R. Sherman (Age 52)
Founder, President, COO & Director
Comp: $790k
Mr. Andrew Lawrence Taylor M.B.A. (Age 52)
Chief Financial Officer
Ms. Inessa R. Wheeler
Vice President of Strategy & Marketing
Mr. William Reed Little (Age 52)
Executive VP of Corporate Development & Strategy
Dr. Yuval Hay Mika D.Sc
Ph.D., GM & CTO of Bioelectronic Therapies
Dr. George Papandreou Ph.D.
Senior VP & GM of Focal Therapies
Dr. Hans-Peter Stoll M.D.
Ph.D., Chief Clinical Officer
Dr. J.C. Simeon
Senior Vice President of Quality
Dr. Avraham Matityahu Fischer M.D. (Age 67)
Senior Vice President of Medical Affairs & Innovation

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

OBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Orchestra BioMed stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchestra BioMed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OBIO shares.
View OBIO analyst ratings or view top-rated stocks.
What is Orchestra BioMed's stock price target for 2024?: 3 Wall Street analysts have issued 1-year price targets for Orchestra BioMed's stock. Their OBIO share price targets range from $15.00 to $20.00. On average, they expect the company's stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 168.0% from the stock's current price.
View analysts price targets for OBIO or view top-rated stocks among Wall Street analysts.
How have OBIO shares performed in 2023?: Orchestra BioMed's stock was trading at $9.12 at the start of the year. Since then, OBIO stock has decreased by 28.4% and is now trading at $6.53.
View the best growth stocks for 2023 here.
When is Orchestra BioMed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our OBIO earnings forecast.

How were Orchestra BioMed's earnings last quarter?: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) released its earnings results on Monday, November, 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.01. The business earned $0.42 million during the quarter, compared to the consensus estimate of $0.89 million.
Who are Orchestra BioMed's major shareholders?: Orchestra BioMed's stock is owned by a number of institutional and retail investors. Top institutional investors include Charles Schwab Investment Management Inc. (0.43%), Northern Trust Corp (0.40%), TD Asset Management Inc (0.26%), Arkadios Wealth Advisors (0.14%), Bank of New York Mellon Corp (0.11%) and The Manufacturers Life Insurance Company (0.11%).
How do I buy shares of Orchestra BioMed?: Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OBIO) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial